Device Trial Radar · NCT07929870
Effectiveness and Safety of Cellbooster Glow in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Feb 1, 2027
Primary completion
Aug 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- SuisselleNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The current post-market clinical investigation is designed to evaluate the efficacy and safety of Cellbooster Glow (CBG). For this purpose, healthy participants with signs of skin aging in the face will receive a 3-session treatment and will be followed-up over 70 days after the initial injection session. Several objective measurements of skin quality will be performed with different instruments allowing to assess skin wrinkles, elasticity, dryness, pigmentation, roughness, overall inflammation and microcirculation. Subjective clinical improvement will be evaluated, as well as participant and investigator satisfactions. The safety of the injections will be assessed by collecting the Injection Site Reactions (ISRs) and Adverse Events (AEs).
Conditions
- Wrinkle Appearance
- Skin Hydration in Healthy Volunteers
- Skin Pigmentation
- Skin Laxity
- Dark Eye Circles (Periorbital Hyperpigmentation)
Interventions
InjectableDevice
An initial injection session will be performed at visit 2 (D0). A second injection session will be performed at visit 3 (D14). And a third injection session will be performed at visit 4 (D28).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline recorded at visit 1 (Day -7 to Day 0) of epidermis hydration measured with Corneometer® at Day 42.Time frame: Day -7 to Day 0 and Day 42.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Eurofins Dermscan Pharmascan
Aix-en-Provence, France
Eurofins Dermscan Pharmascan
Villeurbanne, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.